Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 14/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 6/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16210339 | 0.92 | TRPA1 (0.43) | TRPA1TRPV4P2RX7SCN9ASCN1A | |
| SCHEMBL16210212 | 0.89 | HDAC3 (0.42) | TRPA1SCN9ASCN2ASCN3ASCN10A | |
| SCHEMBL16210492 | 0.87 | TRPA1 (0.46) | TRPA1TRPV4P2RX7 | |
| SCHEMBL16210146 | 0.85 | TRPA1 (0.44) | TRPA1TRPV4P2RX7 | |
| SCHEMBL16210415 | 0.84 | EPHX2 (0.40) | TRPA1P2RX7 | |
| SCHEMBL16209905 | 0.84 | TRPA1 (0.42) | TRPA1TRPV4TRPV3 | |
| SCHEMBL16210211 | 0.81 | HDAC3 (0.42) | TRPA1SCN9ASCN2ASCN10A | |
| SCHEMBL16210144 | 0.77 | TRPA1 (0.44) | TRPA1P2RX7 | |
| SCHEMBL16210228 | 0.76 | TRPA1 (0.45) | TRPA1 | |
| SCHEMBL16209904 | 0.76 | TRPA1 (0.42) | TRPA1TRPV4TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805718-B1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | EA PHARMA CO LTD (JP) | 2018-04-04 | — | — | EP | claimed |
| US-9562043-B2 | Heterocyclic amide derivative and pharmaceutical product containing same | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | claimed |
| EP-2805718-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | Ajinomoto Co., Inc. (JP) | 2014-11-26 | — | — | EP | claimed |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2014-11-06 | — | — | US | claimed |
| EP-2805718-B1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | EA PHARMA CO LTD (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9562043-B2 | Heterocyclic amide derivative and pharmaceutical product containing same | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| EP-2805718-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | Ajinomoto Co., Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885TRPV4 6/4885P2RX7 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.